164 related articles for article (PubMed ID: 12810203)
1. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors.
Lee CT; Genega EM; Hutchinson B; Fearn PA; Kattan MW; Russo P; Reuter VE
Urol Oncol; 2003; 21(3):179-84. PubMed ID: 12810203
[TBL] [Abstract][Full Text] [Related]
2. IMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN CONVENTIONAL RENAL CELL CARCINOMA.
Saker Z; Tsintsadze O; Jiqia I; Managadze L; Chkhotua A
Georgian Med News; 2015 Dec; (249):27-33. PubMed ID: 26719546
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance.
Hofmockel G; Wittmann A; Dammrich J; Bassukas ID
Anticancer Res; 1996; 16(6B):3807-11. PubMed ID: 9042262
[TBL] [Abstract][Full Text] [Related]
4. Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?
Diolombi ML; Cheng L; Argani P; Epstein JI
Am J Surg Pathol; 2015 Dec; 39(12):1621-34. PubMed ID: 26426379
[TBL] [Abstract][Full Text] [Related]
5. Expression of bcl-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma.
Sejima T; Miyagawa I
Eur Urol; 1999; 35(3):242-8. PubMed ID: 10072628
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.
Mytsyk Y; Borys Y; Tumanovska L; Stroy D; Kucher A; Gazdikova K; Rodrigo L; Kruzliak P; Prosecky R; Urdzik P; Dosenko V
Clin Exp Med; 2019 Nov; 19(4):515-524. PubMed ID: 31440867
[TBL] [Abstract][Full Text] [Related]
7. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
Mitsui Y; Hirata H; Arichi N; Hiraki M; Yasumoto H; Chang I; Fukuhara S; Yamamura S; Shahryari V; Deng G; Saini S; Majid S; Dahiya R; Tanaka Y; Shiina H
Oncotarget; 2015 Apr; 6(11):9577-91. PubMed ID: 25797254
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
[TBL] [Abstract][Full Text] [Related]
10. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
[TBL] [Abstract][Full Text] [Related]
11. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.
Krejci KG; Blute ML; Cheville JC; Sebo TJ; Lohse CM; Zincke H
Urology; 2003 Oct; 62(4):641-6. PubMed ID: 14550434
[TBL] [Abstract][Full Text] [Related]
12. Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy.
Sejima T; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Takenaka A
Urol Int; 2012; 88(3):263-70. PubMed ID: 22398398
[TBL] [Abstract][Full Text] [Related]
13. Expression of adipose differentiation-related protein: a predictor of cancer-specific survival in clear cell renal carcinoma.
Yao M; Huang Y; Shioi K; Hattori K; Murakami T; Nakaigawa N; Kishida T; Nagashima Y; Kubota Y
Clin Cancer Res; 2007 Jan; 13(1):152-60. PubMed ID: 17200350
[TBL] [Abstract][Full Text] [Related]
14. Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer.
Virman JP; Bono P; Luukkaala TH; Sunela KL; Kujala PM; Kellokumpu-Lehtinen PL
Clin Genitourin Cancer; 2016 Aug; 14(4):e283-9. PubMed ID: 26821530
[TBL] [Abstract][Full Text] [Related]
15. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
[TBL] [Abstract][Full Text] [Related]
16. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
[TBL] [Abstract][Full Text] [Related]
17. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma.
Uhlman DL; Nguyen PL; Manivel JC; Aeppli D; Resnick JM; Fraley EE; Zhang G; Niehans GA
J Natl Cancer Inst; 1994 Oct; 86(19):1470-5. PubMed ID: 8089867
[TBL] [Abstract][Full Text] [Related]
18. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy.
Harada K; Miyake H; Kusuda Y; Fujisawa M
BJU Int; 2012 Dec; 110(11 Pt C):E1131-7. PubMed ID: 22712620
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
[TBL] [Abstract][Full Text] [Related]
20. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
